Drugs targeting KLK1 have been researched for various applications, including lanoteplase for myocardial infarction, aprotinin for reducing bleeding and transfusion needs during surgery, nafamostat for anticoagulant therapy in acute kidney injury and liver transplantation scenarios, and aniline for the treatment of multiple myeloma. Here, KLK1 is linked to AL amyloidosis.